CODA / CERVA

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com

MEDINA is an independent and non profit entity with innovative research collaborations and contracts with academic and industrial partners worldwide. We are engaged in the discovery of novel drug candidates and new biomarkers with Pharma and Biotech companies and research groups, as well as of new biotechnological products for use in crop protection for the Agrofood industry, Consumer products (Cosmetic and Nutrition) and new enzymes for industrial processes.

MEDINA owns one of the largest Collections of Microbial Strains and the most chemically diverse Natural Products Libraries with a longstanding, successful track record in delivering novel drug candidates for development as pharmaceuticals.

Our team has unique expertise in natural products microbiology, chemistry, high throughput screening, as well as a strong analytical chemistry platform for molecular structure elucidation and bioanalysis.

We are currently active in drug and biomarker discovery programs in infectious diseases (including tuberculosis and parasitic diseases), cancer, CNS, and rare diseases.

Leveraging our unique strengths in high precision-high throughput analytics and bioanalytics we are collaborating with clinical investigators in translational research programs for biomarker discovery and metabolomic profiling of patient samples.

MEDINA is a Research Organization established in the Health Sciences Technology Park, Granada (Spain) as a private-public partnership between the Government of Andalucía (Spain), the University of Granada and Merck Sharp and Dohme de España S.A.

PathoQuest, spin out of Institut Pasteur, is a genomic expert company offering a game-changing next-generation sequencing (NGS) platform for microbiology testing.
The company has developed 2 applications:
• The QC of biological drugs (ATMP, Vaccines, antibodies…) allowing robust and fast analysis under GLP grade.
• The diagnosis of bloodstream Infections (including sepsis) directly from blood.
PathoQuest’s technology combines proprietary sample preparation protocols, applicable to several types of biological samples with proprietary pathogen genome sequence databases and automated analysis pipelines.

BIOLOGICS TESTING OFFER
PathoQuest offers Biotech and biopharmaceutical companies GLP grade solutions to secure the biosafety of biological drugs like cell & gene therapy products, vaccines and, recombinants by preventing adventitious agent contamination and cell-line misidentification.
Advanced NGS-based solutions supplement or replace traditional testing methods and support the strategic decision-making process allowing for a robust and unambiguous level of testing and faster turnaround time.
Based in Paris, France, PathoQuest has established a U.S. subsidiary and is expanding its capabilities by implementing a state-of-the-art testing facility at its location near Philadelphia. The company has also signed in 2018 a strategic partnership with Charles River Lab (Boston, USA)

DIAGNOSIS OF BLOODSTREAM INFECTIONS
- PathoQuest has developed iDTECT® Blood Test, the first and only clinical CE In Vitro Diagnostic (IVD) metagenomic test for infectious diseases.
- The test provides directly from blood to clinicians and microbiologists an improved method for detecting pathogens, particularly for immunocompromised patients with suspected infections. This new molecular diagnostic test is designed to improve antibiotic stewardship and lead to better patient care through personalized treatment.

For more information about PathoQuest, feel free to reach out!

Scanelis is a PCR diagnostic & research laboratory specialized in infectious diseases diagnostics in veterinary medecine : Detection & Quantification of pathogens in animals by quantitative PCR
Scanelis performs day-to-day analyses in a secured lab, dedicated to this technology to provide veterinarians with fast and efficient diagnosis.

Scanelis also provides support to Industry including:
- PCR Diagnostics performed in accordance with a customer's specifications or prescribed quality plan, for instance with the European Pharmacopoeia recommendations.
- Quality Control of biological products derived from animals
- Custom-designed investigations: molecular typing of isolates or strains, infection monitoring and epidemiological monitoring, pathogens or mRNA quantification, cloning and DNA quantification...

Vircell is a biotechnology company specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology-.